Buprenex (buprenorphine) / Reckitt Benckiser 
Welcome,         Profile    Billing    Logout  
 15 Diseases   2 Trials   2 Trials   89 News 


12»
  • ||||||||||  Vivitrol (naltrexone extended-release injectable suspension) / Alkermes, Buprenex (buprenorphine) / Reckitt Benckiser
    Trial completion date, Trial termination:  Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD (clinicaltrials.gov) -  Jun 7, 2023   
    P2,  N=69, Terminated, 
    Trial completion date: Aug 2024 --> Mar 2025 | Trial primary completion date: Aug 2023 --> Mar 2024 Trial completion date: Dec 2021 --> Jan 2023 | Recruiting --> Terminated; Futility analysis
  • ||||||||||  Buprenex (buprenorphine) / Reckitt Benckiser, NN1213 / Novo Nordisk
    Trial completion, Phase classification, Enrollment change:  Buprenorphine Treatment for Opioid Dependence (clinicaltrials.gov) -  Mar 10, 2023   
    P3,  N=9, Completed, 
    Trial completion date: Dec 2021 --> Jan 2023 | Recruiting --> Terminated; Futility analysis Active, not recruiting --> Completed | Phase classification: P1/2 --> P3 | N=20 --> 9
  • ||||||||||  Journal:  Opioids for pain. (Pubmed Central) -  Dec 22, 2022   
    Trial completion date: Dec 2023 --> Aug 2024 | Trial primary completion date: Dec 2022 --> Aug 2023 No abstract available
  • ||||||||||  Sublocade (buprenorphine once-monthly depot) / Indivior
    Review, Journal:  Buprenorphine and its formulations: a comprehensive review. (Pubmed Central) -  Aug 25, 2022   
    Lastly, in order to avoid misuse of buprenorphine for opioid dependence, two combination formulations paired with naloxone were developed: film formulation (Suboxone®) and tablet formulation (Zubsolv®). In this review, we present details of each formulation along with their similarities and differences between each other and clinical considerations.
  • ||||||||||  Buprenex (buprenorphine) / Reckitt Benckiser, NN1213 / Novo Nordisk
    Trial completion date:  Buprenorphine Treatment for Opioid Dependence (clinicaltrials.gov) -  May 27, 2022   
    P1/2,  N=20, Active, not recruiting, 
    In this review, we present details of each formulation along with their similarities and differences between each other and clinical considerations. Trial completion date: Sep 2022 --> Dec 2022
  • ||||||||||  Buprenex (buprenorphine) / Reckitt Benckiser
    Preclinical, Journal:  Serum Buprenorphine Concentrations and Behavioral Activity in Mice After a Single Subcutaneous Injection of Simbadol, Buprenorphine SR-LAB, or Standard Buprenorphine. (Pubmed Central) -  Dec 16, 2021   
    Simbadol is a concentrated formulation of buprenorphine hydrochloride labeled for use in cats with recommended dosing frequency of every 24 h. We measured serum concentrations over time after a single injection of this product in C57BL/6NCrl mice and compared it to standard buprenorphine (Buprenex) and Buprenorphine SR-LAB...We conclude that Simbadol does not offer dosing advantages over the standard buprenorphine formulation when given at 1 mg/kg. Buprenorphine SR-LAB maintained a steady concentration of buprenorphine above 1ng/mL for at least 24 h, and as such is a superior choice for providing long-term analgesia.
  • ||||||||||  Buprenex (buprenorphine) / Reckitt Benckiser, NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  Buprenorphine Treatment for Opioid Dependence (clinicaltrials.gov) -  May 24, 2021   
    P1/2,  N=20, Active, not recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Feb 2021 --> Feb 2022
  • ||||||||||  Vivitrol (naltrexone extended-release injectable suspension) / Alkermes, Buprenex (buprenorphine) / Reckitt Benckiser
    Enrollment open, Trial completion date, Trial primary completion date:  Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD (clinicaltrials.gov) -  May 10, 2021   
    P2,  N=90, Recruiting, 
    Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Feb 2021 --> Feb 2022 Active, not recruiting --> Recruiting | Trial completion date: Sep 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Sep 2021
  • ||||||||||  Vivitrol (naltrexone extended-release injectable suspension) / Alkermes, Buprenex (buprenorphine) / Reckitt Benckiser
    Enrollment change:  Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD (clinicaltrials.gov) -  Apr 19, 2020   
    P2,  N=90, Active, not recruiting, 
    Active, not recruiting --> Recruiting | Trial completion date: Sep 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Sep 2021 N=135 --> 90
  • ||||||||||  Vivitrol (naltrexone extended-release injectable suspension) / Alkermes, Buprenex (buprenorphine) / Reckitt Benckiser
    Enrollment closed:  Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD (clinicaltrials.gov) -  Apr 12, 2020   
    P2,  N=135, Active, not recruiting, 
    N=135 --> 90 Recruiting --> Active, not recruiting
  • ||||||||||  Vivitrol (naltrexone extended-release injectable suspension) / Alkermes, Buprenex (buprenorphine) / Reckitt Benckiser
    Enrollment open:  Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD (clinicaltrials.gov) -  Mar 4, 2020   
    P2,  N=135, Recruiting, 
    Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Buprenex (buprenorphine) / Reckitt Benckiser, NN1213 / Novo Nordisk
    Enrollment closed, Trial completion date, Trial primary completion date:  Buprenorphine Treatment for Opioid Dependence (clinicaltrials.gov) -  Jan 22, 2020   
    P1/2,  N=20, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Sep 2019 --> Sep 2021 | Trial primary completion date: Sep 2019 --> Feb 2021
  • ||||||||||  Vivitrol (naltrexone extended-release injectable suspension) / Alkermes, Buprenex (buprenorphine) / Reckitt Benckiser
    New P2 trial:  Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD (clinicaltrials.gov) -  Feb 25, 2019   
    P2,  N=135, Not yet recruiting, 
  • ||||||||||  Buprenex (buprenorphine) / Reckitt Benckiser, NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  Buprenorphine Treatment for Opioid Dependence (clinicaltrials.gov) -  Sep 5, 2018   
    P1/2,  N=20, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Sep 2019 --> Sep 2021 | Trial primary completion date: Sep 2019 --> Feb 2021 Trial completion date: Mar 2018 --> Sep 2019 | Trial primary completion date: Mar 2018 --> Sep 2019
  • ||||||||||  morphine sulphate / Generic mfg.
    Trial completion, Enrollment change, Trial completion date:  Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS) (clinicaltrials.gov) -  Aug 15, 2018   
    P2,  N=29, Completed, 
    Phase classification: P4 --> P2 Active, not recruiting --> Completed | N=64 --> 29 | Trial completion date: Apr 2018 --> Oct 2017
  • ||||||||||  Buprenex (buprenorphine) / Reckitt Benckiser, NN1213 / Novo Nordisk
    Trial completion, Phase classification, Enrollment change:  IRLGREY-B: Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine (clinicaltrials.gov) -  Jul 3, 2018   
    P4,  N=31, Completed, 
    Active, not recruiting --> Completed | N=64 --> 29 | Trial completion date: Apr 2018 --> Oct 2017 Active, not recruiting --> Completed | Phase classification: P3 --> P4 | N=100 --> 31
  • ||||||||||  morphine sulphate / Generic mfg.
    Enrollment closed, Trial primary completion date:  Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS) (clinicaltrials.gov) -  Mar 30, 2018   
    P2,  N=64, Active, not recruiting, 
    Active, not recruiting --> Completed | Phase classification: P3 --> P4 | N=100 --> 31 Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Nov 2017
  • ||||||||||  Buprenex (buprenorphine) / Reckitt Benckiser
    New trial, Surgery, Bariatric surgery:  Bariatric Surgery and Pharmacokinetics of Buprenorphine (clinicaltrials.gov) -  Mar 9, 2018   
    P=N/A,  N=12, Recruiting, 
  • ||||||||||  Buprenex (buprenorphine) / Reckitt Benckiser
    Enrollment change:  BUP-TRD: Buprenorphine for Treatment Resistant Depression (clinicaltrials.gov) -  Mar 18, 2016   
    P3,  N=13, Completed, 
    Trial primary completion date: Dec 2015 --> Jun 2017 N=20 --> 13
  • ||||||||||  Buprenex (buprenorphine) / Reckitt Benckiser
    Enrollment change:  Buprenorphine Treatment for Opioid Dependence (clinicaltrials.gov) -  Nov 17, 2015   
    P1/2,  N=20, Recruiting, 
    Trial primary completion date: Dec 2015 --> Dec 2016 N=200 --> 20
  • ||||||||||  Buprenex (buprenorphine) / Reckitt Benckiser
    Enrollment open, Trial initiation date:  Buprenorphine Treatment for Opioid Dependence (clinicaltrials.gov) -  Jul 15, 2015   
    P1/2,  N=200, Recruiting, 
    N=200 --> 20 Not yet recruiting --> Recruiting | Initiation date: Jul 2014 --> Mar 2015
  • ||||||||||  Buprenex (buprenorphine) / Reckitt Benckiser
    New P1/2 trial:  Buprenorphine Treatment for Opioid Dependence (clinicaltrials.gov) -  Jul 12, 2014   
    P1/2,  N=200, Not yet recruiting,